Overview

A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT

Status:
Completed

Trial end date:
2019-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the intraocular pressure-lowering effect and the safety of DE-117 ophthalmic solution compared with Latanoprost ophthalmic solution in subjects with open angle glaucoma or ocular hypertension.

Phase:

Phase 3

Details

Lead Sponsor:

Santen Pharmaceutical Co., Ltd.

Treatments:

Latanoprost
Ophthalmic Solutions
Pharmaceutical Solutions